INmune Bio Reports First Quarter 2019 Financial Results

INmune Bio (NASDAQ:INMB) has reported its financial results for the first quarter ended March 31, 2019.

As quoted in the press release:

Corporate Highlights in 2019:

• First biotechnology company to close initial public offering in 2019 and commence trading on The Nasdaq Capital Market.
• Received the Part the Cloud Award from the Alzheimer’s Association, including a $1 million grant to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer’s disease.

“2019 has marked a transformative period for INmune Bio, as the first biotech of the year to close its IPO and list on the Nasdaq,” stated RJ Tesi, M.D., Chief Executive Officer of INmune Bio. “We are focused on advancing our clinical programs for the foreseeable future.”

Our clinical programs continue to advance:

• INB03, our program targeting resistance to immunotherapy caused by myeloid derived suppressor ells (MDSC), completing a monotherapy Phase I trial in patients with advanced solid tumors, will transition into a combination therapy clinical program this summer in preparation for a Phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC that should begin in 2020.  INB03 targets MDSC – one of the causes of resistance to checkpoint inhibitors.  Treatment with INB03 should eliminate the MDSC in the tumor microenvironment to allow CPI to be therapeutically effective.
• INKmune, our NK cell therapy focused on eliminating residual disease after cancer therapy will start enrolling patients in a Phase I/II trial in women with relapsed refractory ovarian cancer later this year.  In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of their NK cells to eliminate minimal residual disease (MRD).  INKmune, by priming the patient’s NK cells to attack their tumor, should eliminate MRD to prevent relapse.

Click here to read the full press release.